ClinicalTrials.gg
Not yet recruitingNCT07111130RE-BALANCEUpdated May 15, 2026

Restoring Bile Acid Homeostasis Via Lifestyle Adjustments to Prevent the Development of Liver Cancer

An interventional study of 12-week Lifestyle Intervention in Liver Diseases, sponsored by National Cancer Centre, Singapore. Not yet recruiting at 14 sites in Singapore. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by National Cancer Centre, Singapore · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Liver Diseases with a site in Singapore — 4 open to participants now, 6 under way, 2 of them phase 3. Liver Diseases · Singapore.

Planned enrollment
7th of 12
90 · median 92
Started
2026
with 1 other
No phase
Only one
of the 14
Registered
13th of 14
by date
Lead sponsor
2 of 14
National Cancer Centre, Singapore

Among the 14 studies in Liver Diseases with a site in Singapore, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one with no phase, and was the 13th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

4 of the 14 studies in Liver Diseases with a site in Singapore are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 105 Liver Diseases studies recruiting now, 52 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Liver Diseases with a site in Singapore, or all of them as a file.
02

Study summary

This is a prospective, single-arm, non-randomized interventional study nested within the existing ELEGANCE cohort. Patients eligible for the RE-BALANCE study will be selected from the ELEGANCE cohort based on predefined high-risk criteria, specifically a low 12-non-hydroxy/12-hydroxy bile acid ratio indicative of elevated hepatocarcinogenic risk.

The study comprises Baseline Assessments (Visit 1), Intervention Visits (Visit 2-8), and Follow-up Assessments (Visit 9-11).

Read the detailed description

Participants will undergo a structured 12-week lifestyle intervention comprising a low-carbohydrate, high-fibre dietary plan and a prescribed physical activity program targeting at least 150 minutes of moderate-intensity exercise per week. Standardized meal provision and wearable fitness tracking devices will be used to support adherence throughout the intervention period.

Biological assessments will be conducted at baseline (Visit 1), mid-intervention (Visit 6), and end-of-intervention (Visit 9), including blood sampling for bile acid profiling and stool sampling for gut microbiome sequencing. Liver health evaluation will be conducted at baseline (Visit 1) and end-of-intervention (Visit 9) to assess patient's change in liver health. Extended biological assessments (Visit 10-11) and liver health evaluation through LMS-CT1 imaging (Visit 11) will be performed post-intervention to evaluate the sustainability of the observed changes.

Participants will continue to receive standard-of-care surveillance in parallel during the study. In the event of clinical suspicion for hepatocellular carcinoma during surveillance imaging, participants will undergo confirmatory diagnostic imaging and, if diagnosed, will be referred for standard clinical management. Participants diagnosed with HCC during the study will be withdrawn from the active intervention phase. Their data up to the point of diagnosis will be included in analysis, and they will revert to standard-of-care HCC management. Ongoing follow-up for clinical outcomes may continue under the parent ELEGANCE study framework.

The study will enrol approximately 90 high-risk NBNC patients identified from the ELEGANCE cohort. Accrual is expected to be completed within 6 to 9 months. The active intervention will last 12 weeks, with subsequent observational follow-up extending up to 12 months post-intervention to assess the durability of metabolic, microbiome, and imaging changes and monitor the incidence of hepatocellular carcinoma.

03

Conditions studied

  • Liver Diseases

Keywords

  • Hepatocellular Carcinoma (HCC)
  • Non-viral HCC
  • Interventional Study
  • Lifestyle Adjustments
  • Bile Acid, Microbiome and Liver Health Modulation
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The following criteria are to be checked at the time of enrolment. The patient may only be included in the study if ALL of the following statements are FULFILLED:

  1. The patient is an existing participant of the ELEGANCE study and shows no evidence of hepatocellular carcinoma (HCC) at the time of enrolment into RE-BALANCE.
  2. Male and female patients aged 50 to 90 years at the time of are eligible. However, patients with cirrhosis may be included if they are aged 40 to 90 years.
  3. Negative for surface antigen (HBsAg) and antibody
  4. High-risk bile acid profile, defined as a 12-non-hydroxy/12-hydroxy bile acid ratio below the threshold determined from ELEGANCE cohort data.
  5. Patient is able to comply with scheduled visits, assessments and other study procedures.
  6. Patient is willing to provide informed consent before enrolment in the study.

Exclusion criteria

Exclusion Criteria:

The following criteria should be checked at the time of enrolment. If ANY applies, the patient must not be included in the study:

  1. Patient with confirmed diagnosis of HCC by the American Association for the Study of the Liver Disease (AASLD) imaging criteria or histology / cytology within the last 5 years.
  2. Patient with C or decompensated cirrhosis at time of enrolment (based on the judgement of the Investigator).
  3. Patient with active hepatic encephalopathy at time of enrolment.
  4. Patient is known to be positive for the (HIV).
  5. Patient has chronic liver diseases apart from steatosis or compensated cirrhosis (e.g., hepatitis, primary biliary cholangitis. etc.).
  6. Uncontrolled diabetes mellitus requiring special dietary management or persistent unacceptable levels.
  7. Use of weight-loss medications (e.g., GLP-1 agonists, Orlistat) within three months prior to enrolment or planned use during the study period.
  8. History of bariatric surgery or planned bariatric surgery during the study period.
  9. Patient has significant comorbidities expected to limit to less than one year, or that would render diet or exercise unsafe

    1. Diseases involving muscles, bones or joints that may impact the subjects' performance during exercise testing and exercise rehabilitation
    2. Co-morbidities that may adversely affect exercise performance
    3. Requiring an assistive aid with walking
    4. Conditions that require strict dietary restrictions or impair ability to follow dietary interventions
  10. Patient has significant gastrointestinal diseases affecting nutrient absorption or requiring a special diet incompatible with study diet.
  11. Pregnancy or breastfeeding
  12. Current use of medications or supplements that significantly alter bile acid gastrointestinal absorption (e.g., bile acid sequestrants) that cannot be safely discontinued.
  13. Patient has severe food allergies or intolerances incompatible with the provided study diet.
  14. Patient has psychiatric or addictive disorders that may compromise his/her ability to give , or to comply with the study procedures.
  15. Patient is unable to provide informed consent or refuse blood taking and other investigations including LMS scans.
  16. Patient has any other condition which, in the opinion of the Investigators, would make the patient unsuitable for enrolment or could interfere with completion of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    12-week Intervention

    12-week lifestyle intervention.

    Other: 12-week Lifestyle Intervention

Interventions

  • Other12-week Lifestyle Intervention

    Eligible participants within the existing ELEGANCE cohort will undergo a structured 12-week lifestyle intervention comprising a low-carbohydrate, high-fibre dietary plan and a prescribed physical activity program targeting at least 150 minutes of moderate-intensity exercise per week. Standardized meal provision and wearable fitness tracking devices will be used to support adherence throughout the intervention period.

06

What researchers measure

Primary outcomes

  1. Hepatocarcinogenic risk change in relation to metabolomics profile.

    Change in the bile acid profile pre- and post-intervention.

    Time frame: Pre-intervention (Baseline), Post-intervention (3-month)

  2. Hepatocarcinogenic risk change in relation to metagenomics profile.

    Change in the gut microbiome alpha and beta diversity pre- and post-intervention.

    Time frame: Pre-intervention (Baseline), Post-intervention (3-month)

  3. Hepatocarcinogenic risk change in relation to liver health profile.

    Change in the hepatic steatosis and fibrosis as measured by LMS-CT1 MRI pre- and post-intervention.

    Time frame: Pre-intervention (Baseline), Post-intervention (3-month)

  4. Sustained change in hepatocarcinogenic risk in relation to metabolomics profile.

    Sustained change in the bile acid profile post-intervention.

    Time frame: Up to 12 months.

  5. Sustained change in hepatocarcinogenic risk in relation to metagenomics profile.

    Sustained change in the gut microbiome alpha and beta diversity post-intervention.

    Time frame: Up to 12 months.

  6. Sustained change in hepatocarcinogenic risk in relation to liver health profile.

    Sustained change in the hepatic steatosis and fibrosis as measured by LMS-CT1 MRI post-intervention.

    Time frame: Up to 12 months.

  7. Long-term HCC incidence against a matched control within the ELEGANCE cohort.

    Time frame: Up to 12 months.

07

Study locations

14 sites
  • National University Hospital
    Singapore, 119074, Singapore
  • SingHealth Polyclinics - Bukit Merah
    Singapore, 150163, Singapore
  • National Cancer Center Singapore
    Singapore, 168583, Singapore
    • Professor Pierce CHOW, MD, PhD · Contact
  • SingHealth Polyclinics - Outram
    Singapore, 168937, Singapore
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
  • SingHealth Polyclinics - Marine Parade
    Singapore, 440080, Singapore
  • SingHealth Polyclinics - Bedok
    Singapore, 469662, Singapore
  • SingHealth Polyclinics - Pasir Ris
    Singapore, 519466, Singapore
  • SingHealth Polyclinics - Tampines
    Singapore, 529203, Singapore
  • Changi General Hospital
    Singapore, 529889, Singapore
  • Sengkang General Hospital
    Singapore, 544886, Singapore
  • SingHealth Polyclinics - Sengkang
    Singapore, 545025, Singapore
  • SingHealth Polyclinics - Punggol
    Singapore, 820681, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Mar 2027, 8 months later.

Of 122 non-industry interventional studies with no phase under Liver Diseases, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 8 months is below that.

Counting every sponsor, half of 135 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Aug 8, 2025
StartEst.
Jul 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2028
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07111130
Collaborators
Perspectum, BUZUD Pte Ltd, Asian Microbiome Library (AMiLi) Pte Ltd
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Jul 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
May 15, 2026

Study contacts

Professor Pierce Chow, MD, PhD
Contact
pierce.chow.k.h@singhealth.com.sg
+65 6306 5424
Dr Yuxin GUO, MD
Contact
guo.yuxin@singhealth.com.sg
Professor Pierce Chow, MD, PhD
study chair · National Cancer Centre, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion